Progenics Pharmaceuticals Inc (USD)
PGNX
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range3.77 | 3.96
52-Wk Range- | -
Last Close3.96
Mkt Cap (m)342.92
Dividend yield-
ISINUS7431871067
Volume355,399.00
Exchange VenueNAS

Company Profile

Progenics Pharmaceuticals Inc is a biopharmaceutical company that develops innovative medicines and other technologies to identify, target and treat cancer. Its pipeline drugs include AZEDRA and 1095; 1404 and PyL; and imaging analysis tools.

Key Information
Price/Earning-
Price/Book11.20
Price/Sales9.23
P/CF-
Rev Growth (3 year avg)-20.42
EPS Growth (3 year avg)-
Operating Margin % -186.48
Net Margin %-195.94
Return on Equity-92.87
Debt/Equity1.17

Documents

Prospectus
en 08/08/2018
Annual Report
en 31/12/2019

Financials

Income Statement
USD201420152016201720182019
Revenue (m)44.388.6869.4311.7015.6234.99
Operating Income (m)7.55-37.708.50-55.80-48.96-65.24
Net Income (m)4.41-39.1110.81-51.01-67.66-68.55
Basic EPS0.06-0.560.15-0.73-0.87-0.80
Avg. Diluted Shares Outstanding (m)68.2469.7270.1670.2877.8985.61
Balance Sheet
USD201420152016201720182019
Current Assets (m)121.9383.29148.1096.87144.1363.73
Non Current Assets (m)39.1147.9750.8949.0925.3755.74
Total Assets (m)161.04131.25198.99145.96169.50119.47
Current Liabilities (m)6.699.7316.3615.3623.4522.07
Total Liabilities (m)------
Total Equity (m)124.9190.46104.7663.45101.0846.55
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)13.73-40.1419.21-53.63-46.75-74.70
Capital Expenditure (m)-0.71-0.37-4.29-0.27-0.82-15.23
Figures are quoted in USD unless stated otherwise
-
No change
$
3.96
Last Price